(Q79862363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

main subject

systemic immune response

1 reference

Brian R Sloat

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Zhengrong Cui

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

19 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

6405-6413

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

40-41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

Regulation of the Bacillus anthracis protective antigen gene: CO2 and a trans-acting element activate transcription from one of two promoters

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Anthrax as a biological weapon, 2002: updated recommendations for management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Identification of the cellular receptor for anthrax toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Anthrax toxin: a tripartite lethal combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Plasmid-associated virulence factors of non-toxigenic (pX01−) Bacillus anthracis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

A dually active anthrax vaccine that confers protection against both bacilli and toxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Anthrax capsule vaccine protects against experimental infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

In vitro correlate of immunity in a rabbit model of inhalational anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Toll-like receptor ligands directly promote activated CD4+ T cell survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Toll-like receptor 3 promotes cross-priming to virus-infected cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Biosynthesis and ultrasonic degradation of bacterial poly(gamma-glutamic acid)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Topical immunization using nanoengineered genetic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Therapeutics targeting the innate immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.06.002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16828937%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference